title: Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence.
abstract: BACKGROUND
  Osteosarcoma is the most common malignant primary bone tumour in young adult treated by neo adjuvant chemotherapy, surgical tumor removal and adjuvant multidrug chemotherapy. For correction of soft tissue defect consecutive to surgery and/or tumor treatment, autologous fat graft has been proposed in plastic and reconstructive surgery.
  
  
  RESULTS
  We report here a case of a late local recurrence of osteosarcoma which occurred 13 years after the initial pathology and 18 months after a lipofilling procedure. Because such recurrence was highly unexpected, we investigated the possible relationship of tumor growth with fat injections and with mesenchymal stem/stromal cell like cells which are largely found in fatty tissue. Results obtained in osteosarcoma pre-clinical models show that fat grafts or progenitor cells promoted tumor growth.
  
  
  CONCLUSIONS
  These observations and results raise the question of whether autologous fat grafting is a safe reconstructive procedure in a known post neoplasic context.
authors.affiliation: INSERM, U957, Nantes, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Perrot
authors.forename: Julie
authors.initials: J
authors.lastname: Rousseau
authors.forename: Anne-Laure
authors.initials: AL
authors.lastname: Bouffaut
authors.forename: Françoise
authors.initials: F
authors.lastname: Rédini
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Cassagnau
authors.forename: Frédéric
authors.initials: F
authors.lastname: Deschaseaux
authors.forename: Marie-Françoise
authors.initials: MF
authors.lastname: Heymann
authors.forename: Dominique
authors.initials: D
authors.lastname: Heymann
authors.forename: Franck
authors.initials: F
authors.lastname: Duteille
authors.forename: Valérie
authors.initials: V
authors.lastname: Trichet
authors.forename: François
authors.initials: F
authors.lastname: Gouin
mesh_terms: D000273:Adipose Tissue / Q000637:transplantation*; D000818:Animals; D045744:Cell Line, Tumor; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D059630:Mesenchymal Stem Cells / Q000166:cytology*; D051379:Mice; D008809:Mice, Inbred C3H; D012516:Osteosarcoma / Q000473:pathology* / Q000628:therapy; D012008:Recurrence